Pfizer shares climb 1.15 percent

By Sumit Modi

Shares of New York-based pharmaceutical company Pfizer have increased 1.15 percent to $37.31 as it prepares to release this year's second quarter earnings later today.

It is expected that the earnings will reach around 62 cents on revenue of $13.01 billion. This time last year, earnings were 56 cents on revenue of $11.85 billion.

Pfizer also announced this week that it has acquired Bamboo Theapeutics for $150 million, expanding its gene therapy biotechnology expertise. 

Pfizer will take over Bamboo's manufacturing facility and any treatments which are currently in development. It had previously collaborated with Spark Therapeutics to create a treatment for hemophilia B.

According to The Street, Mikael Dolsten, Head of Research and Development at Pfizer, said: "We believe that gene therapy holds the promise of bringing true disease modification for patients suffering from devastating diseases."


Follow @BizReviewUSA and @NellWalkerMG

Read the July issue of Business Review USA & Canada here


Featured Articles

DEI done right: Brook Sims, COO, MAC Diversity Recruiters

Passionate about helping others find their voice, diversity leader and COO Brook Sims talks powerful leadership, diverse teams and being a change agent

Q&A: China’s ecommerce innovator Jeff Li, CEO of Shoplazza

Named in Fortune China’s 40 under 40 for 2022, former Baidu head Jeff Li is the entrepreneurial founder and CEO of ecommerce platform Shoplazza

How hybrid work is revolutionising the physical office

As hybrid work models roll out worldwide, the purpose of the office is changing with collaboration, connection and networking taking centre stage

Trailblazer: Shanique Bonelli-Moore, DEI chief at Clorox


Dean Forbes – the Forterro CEO aiming for the moon

Leadership & Strategy

Why becoming a B Corp is good for business